Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
4 citations
,
January 2023 in “Skin health and disease” Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
3 citations
,
November 1998 in “PubMed” September 2023 in “Journal of the American Academy of Dermatology” 2 citations
,
May 2024 in “Expert Opinion on Drug Safety” Infections during JAK inhibitor treatment for alopecia areata are usually manageable and rarely stop treatment permanently.
33 citations
,
August 1973 in “American Heart Journal” Propranolol can cause reversible hair loss.
18 citations
,
October 2010 in “Bioorganic & Medicinal Chemistry Letters” New hybrid compound found to effectively prevent hair loss.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” 15 citations
,
October 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.
22 citations
,
January 1985 in “Annals of Internal Medicine” Minoxidil in breast milk may harm nursing infants.
4 citations
,
June 2024 in “British Journal of Dermatology” EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.
11 citations
,
June 2019 in “Journal of dermatology” New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
October 2024 in “BMJ Case Reports” Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.
4 citations
,
October 2000 in “Contraception” The right dosage of CPA and TB can work as a safe and reversible male contraceptive in monkeys.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
April 2010 in “Nature Reviews Urology”
April 2025 in “JAAD Case Reports” Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
2 citations
,
November 2025 in “Pharmacology Research & Perspectives” Avacopan may cause unexpected side effects, so early monitoring is important.
4 citations
,
April 2024 in “Cellular and Molecular Biology” Injectable platelet-rich fibrin is better than platelet-rich plasma for promoting hair growth.
3 citations
,
May 2025 in “Frontiers in Pharmacology” Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
March 2026 in “Dermatology Online Journal” Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
December 2025 in “Clinical and Translational Science” EGFR inhibitors in breast cancer treatment can cause serious skin issues affecting patient quality of life.
July 2022 in “British Journal of Dermatology” January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
August 2024 in “Journal of Personalized Medicine” Tamsulosin increases the risk of floppy iris during eye surgery.
January 2020 in “Nihon Yakuri Gakkai nenkai yoshishu” Minoxidil protects brain tissue directly, not by lowering blood pressure.
January 2025 in “Biochemical Pharmacology” Peficitinib can turn human fibroblasts into cells that help grow hair.
5 citations
,
December 2015 in “PubMed” Some gonadal hormone drugs can block filovirus entry into cells.